MUMBAI (Reuters) - India's Ranbaxy Laboratories Ltd fell 4.4 percent in pre-open trading on Friday after the U.S. Food and Drug Administration (FDA) revoked tentative approval for certain generic drugs.
via Reuters: Health News Read More Here..
No comments:
Post a Comment